Senior living & memory care

What an MMSE or MoCA Score Says About Dementia Stage

Save

Families often leave an appointment with a number and no idea what it means. The MMSE and the MoCA are screening tests: they sample memory, attention, and language and produce a score out of a fixed total. Staging asks a different question — how much of daily life a person can still manage on their own. This page explains how the two relate, and where the number stops being useful.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Does an MMSE or MoCA score tell you the stage?

No — not on its own. The MMSE and the MoCA are screening tests. They sample cognition in about ten minutes and return a number. A stage is a statement about function: how much of dressing, cooking, managing medication, and staying safe a person still handles without help. Dementia is defined as loss of cognitive function severe enough to interfere with daily life 1, and it is that interference the stages track.

A score is evidence toward a stage. It is not the stage itself. Clinicians read it alongside what a family member reports about the last six months, a physical exam, and sometimes imaging or bloodwork. When the score and the story disagree, the story usually carries more weight, because the story is measuring the thing the definition of dementia actually names.

What the MMSE and the MoCA actually measure

Both are brief screens, and both were built for a purpose narrower than staging. The Mini-Mental State Examination was introduced in 1975 as a five-to-ten-minute clinician-administered screen of cognitive state, organised as eleven question groups covering orientation, registration, attention and calculation, recall, and language, scored from 0 to 30, with a higher score meaning better function 2. Its authors presented it as a practical way to grade cognitive state — a screen, not a diagnosis 2.

The Montreal Cognitive Assessment came later. Published in 2005, it was purpose-built as a roughly ten-minute screen for mild cognitive impairment — measurable decline in thinking that has not yet crossed into interference with independent daily life — and its validation study used a cutoff score of 26 3.

The difference in what the two catch is large. In that validation study, at a cutoff of 26, the MoCA identified 90% of the participants with mild cognitive impairment while the MMSE identified 18%; for participants with mild Alzheimer's disease the figures were 100% and 78%. Specificity ran the other direction — 87% for the MoCA and 100% for the MMSE 3.

At a cutoff of 26, the MoCA identified 90% of mild-cognitive-impairment cases in its validation study; the MMSE identified 18% 3.

That trade is worth understanding before reading anything into a result. The MMSE rarely calls a healthy person impaired. It frequently misses someone who is.

Staging instruments ask a different question

Staging tools were built to describe the arc of an illness rather than to detect it, and they gather different evidence to do it. The Clinical Dementia Rating, introduced in 1982, is a clinician-administered global rating device developed for a prospective study of mild Alzheimer-type dementia; it was shown to distinguish unambiguously among older adults across a wide range of cognitive function, from healthy to severely impaired 4. It is not a screening or diagnostic test.

The Global Deterioration Scale, published the same year, set out seven stages of primary degenerative dementia 5. The Functional Assessment Staging tool that followed in 1988 kept seven major stages and added substages — 6a through 6f and 7a through 7f — describing functional decline step by step 6.

What all three share is that they are scored from what a person does, usually with an informant who sees them most days, rather than from a bedside quiz. This is why a dementia staging assessment in a clinic often takes longer than the cognitive test that preceded it.

A screen and a stage are different instruments

Holding the two side by side makes the mismatch plain. One is a short, standardised sample of cognitive performance taken in a single sitting. The other is a structured judgment about capability across months. They answer different questions, and a thorough assessment uses both. The table below shows the shape of that difference — it is not a conversion chart, because no arithmetic turns one column into the other.

Screening test (MMSE, MoCA)Staging instrument (CDR, GDS, FAST)
Question it answersIs thinking impaired right now?How far has the illness progressed?
Where the information comes fromThe person, in the roomAn informant plus the clinician's judgment
What it producesA scoreA stage
What it was built forDetectionDescribing the course
Time frame it coversOne sittingMonths of daily function
Usable in late illnessOften not — the person cannot complete itYes — it describes what remains

Why there is no official score-to-stage conversion chart

Charts assigning score bands to stages circulate widely, and Gale does not publish one. The reason sits in the source material: the papers that define these instruments do not define a crosswalk between them. The MMSE's original report grades cognitive state; it does not map scores onto stages 2. The staging scales were built from function and behaviour, not from test performance 56.

The correspondence that does exist is loose and directional. Someone in the earliest stage usually scores near the top of a screening test. Someone in a late stage often cannot complete one at all — the test bottoms out, and further decline produces no further movement in the number. In the middle, the spread of scores at any given stage is wide enough that a single number is a poor way to place a person.

There is a second reason those charts mislead. Bands are often quoted as though the instrument's authors set them. The widely repeated 23/24 MMSE threshold is not from the 1975 paper 2; a cutoff belongs to the particular validation study that produced it, in the particular population it was produced in, and it does not travel unchanged to everyone.

If a chart online placed your parent in a stage and the clinic did not, the clinic is working from more information, not less.

Do repeat scores show the disease progressing?

Serial scores tell you more than one score does, but they carry a limit that is rarely said out loud. Neither the MMSE's original paper nor the MoCA's defines how many points constitute a meaningful change — no minimal clinically important difference and no minimal detectable change appears in either 23. A two-point drop between visits may be real decline, or it may be the ordinary variability of a short test taken on a different morning.

What clinicians weigh instead is the direction across several visits, read against what changed at home: a medication that stopped being taken correctly, a stove left on, a familiar route that stopped being familiar, a bill that went unpaid for the first time in fifty years. Those observations are what move a stage. Tracking dementia stage progression is mostly the work of noticing which tasks dropped away, and when.

One score is a data point. Three scores plus a caregiver's account are a trend, and only the trend means anything.

Where the number stops mattering and function takes over

Late in the illness, screening scores lose their usefulness entirely, and functional staging carries the decisions on its own. The FAST scale exists partly for this reason: its stage 7 substages describe the loss of speech, of walking, of sitting up, of holding the head up, and those markers are what dementia hospice eligibility is written around 6. No cognitive test distinguishes among those states, because a person at that point cannot take one.

The same logic applies much earlier, to the decisions families are actually making. Whether someone can be left alone for an afternoon. Whether the stove needs disabling. Whether behavioral symptoms by stage have changed what the household needs at night. None of these is answered by a score; each is answered by watching function and describing it accurately to the clinician.

GDS stage 7 and the late FAST substages get the most attention because that is where formal eligibility rules attach. But every stage judgment, early or late, runs on the same kind of evidence.

What to ask when you are handed a score

A number without context is the most common way a family leaves an appointment more frightened than they arrived. A short set of questions turns it into something usable, and clinicians generally expect to be asked them. It is reasonable to write the answers down in the room, because a number remembered without its scale is worse than no number at all.

  • Which test was this, and what is the highest possible score on it?
  • Has this test been done here before, and what was the result then?
  • What stage would you place them in, and which staging tool are you using — CDR, GDS, or FAST?
  • What did I describe today that changed your answer?
  • What would you expect to be different by the next visit?

Different dementia stage models divide the same illness differently — some clinicians speak in three broad stages, others in seven — so a stage named without its scale is ambiguous. Asking which scale sits behind the word is not pedantry. It is the difference between "moderate" meaning one thing and meaning something else entirely.

Common questions

There is no official answer, which is why sources disagree. The MMSE's own paper grades cognitive state and does not assign scores to stages, and the staging scales were built from function rather than test performance. Score bands published as though they were standard are usually borrowed from one study's population. A clinician sets moderate from what a person can still do, with the score as one input.

For catching mild impairment, yes, and by a wide margin in its original validation. The MMSE's strength is the opposite: it very rarely labels a healthy person impaired. Neither is a diagnosis. Which one a clinic uses often comes down to licensing, training, and what has been used with that person before, since a comparison to a prior result is more informative than a first score.

A score below a screening cutoff means the screen was positive, not that a diagnosis has been made. Dementia requires cognitive loss severe enough to interfere with daily life, which no ten-minute test can establish. A positive screen normally leads to a fuller evaluation: history from someone who knows the person well, an exam, bloodwork, and sometimes imaging to look for treatable causes.

Yes, and this is the most important limitation of screening tests. In the MoCA's validation study the MMSE identified fewer than one in five people with mild cognitive impairment. Someone with strong verbal skills, high education, or a long habit of covering gaps can score in the normal range while a spouse watches daily function slip. A normal score does not close the question when the story says otherwise.

Often, but not reliably from one repeat. Neither instrument's original paper defines how many points count as a meaningful change, so a small drop can reflect a bad night, an infection, hearing difficulty, a different examiner, or genuine decline. Clinicians look at the direction over several visits and at whether anything at home has changed alongside it.

Functional staging rather than a cognitive score. The FAST scale describes decline through seven major stages with substages, and its stage 7 markers — loss of intelligible speech, of walking, of sitting up, of holding the head up — are what dementia hospice criteria are written around. A person at that point generally cannot complete a cognitive screen, so a score would have nothing to say.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When a change in thinking is not staging — it is urgent

  • —Confusion, drowsiness, or agitation that comes on over hours to a few days rather than over months, especially alongside fever, a cough, burning with urination, or a recent fall — that pattern suggests delirium from an infection or a medication, which is treatable and often reversible.
  • —New weakness or drooping on one side of the face or body, sudden trouble speaking or understanding speech, or sudden loss of vision.
  • —Any blow to the head in a person taking a blood thinner, even if they seem entirely fine afterward and even if the fall looked minor.
  • —A sharp drop on a repeat cognitive test within weeks, particularly with new unsteadiness, new incontinence, or a headache that is worse in the morning.

Sudden weakness, facial droop, or trouble speaking is treated as a stroke until proven otherwise — that is a 911 call, not a wait for the next appointment. A head injury in someone on a blood thinner is an emergency department visit the same day.

This page explains how cognitive screening tests and dementia staging instruments differ. It is general information, not medical advice, and it cannot stage anyone or interpret a particular score. Only a clinician who has examined the person and heard from someone who lives with them can do that.

References

  1. 1.National Institute on Aging (NIH) (2022). What Is Dementia? Symptoms, Types, and Diagnosis. National Institute on Aging (NIH). link ✓The definition of dementia as loss of cognitive function severe enough to interfere with daily life — the functional criterion that staging instruments track and that a screening score does not measure.
  2. 2.Folstein MF, Folstein SE, McHugh PR. (1975). "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189-198. doi:10.1016/0022-3956(75)90026-6 ✓The MMSE's origin and purpose as a brief clinician-administered screen of cognitive state (not a diagnostic test), its eleven question groups across orientation, registration, attention and calculation, recall and language, its 0-30 range and higher-is-better direction; and the negative claims that this paper defines no score-to-stage mapping, no minimal clinically important difference or minimal detectable change, and is not the source of the widely repeated 23/24 cutoff.
  3. 3.Nasreddine ZS, Phillips NA, Bédirian V, et al. (2005). The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53(4):695-9. doi:10.1111/j.1532-5415.2005.53221.x ✓The MoCA's purpose as a roughly ten-minute screen built for mild cognitive impairment, its cutoff score of 26, and the head-to-head detection figures from its validation study (MoCA 90% of MCI and 100% of mild Alzheimer's disease versus MMSE 18% and 78%; specificity 87% MoCA versus 100% MMSE); and the negative claim that it defines no threshold for a meaningful change in score.
  4. 4.Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982). A New Clinical Scale for the Staging of Dementia. The British Journal of Psychiatry. doi:10.1192/bjp.140.6.566 ✓The Clinical Dementia Rating's origin as a clinician-administered global staging device developed for a prospective study of mild Alzheimer-type dementia, its distinction from a screening or diagnostic test, and its demonstrated ability to separate older adults across the range from healthy to severely impaired.
  5. 5.Reisberg B, Ferris SH, de Leon MJ, Crook T (1982). The Global Deterioration Scale for assessment of primary degenerative dementia. American Journal of Psychiatry. doi:10.1176/ajp.139.9.1136 ✓The existence and seven-stage structure of the Global Deterioration Scale for primary degenerative dementia, and that it is a staging framework built from clinical deterioration rather than from cognitive test scores.
  6. 6.Reisberg B (1988). Functional Assessment Staging (FAST). Psychopharmacology Bulletin. PMID 3249767The FAST scale's seven major stages with substages 6a-6f and 7a-7f describing functional decline in Alzheimer's dementia, its basis in function rather than test performance, and the stage 7 markers used in dementia hospice eligibility.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library